{"id":760107,"date":"2023-05-23T16:10:05","date_gmt":"2023-05-23T20:10:05","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/immunome-publishes-preclinical-research-demonstrating-that-inhibition-of-il-38-using-an-antibody-leads-to-anti-tumor-activity\/"},"modified":"2023-05-23T16:10:05","modified_gmt":"2023-05-23T20:10:05","slug":"immunome-publishes-preclinical-research-demonstrating-that-inhibition-of-il-38-using-an-antibody-leads-to-anti-tumor-activity","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/immunome-publishes-preclinical-research-demonstrating-that-inhibition-of-il-38-using-an-antibody-leads-to-anti-tumor-activity\/","title":{"rendered":"Immunome Publishes Preclinical Research Demonstrating that Inhibition of IL-38 Using an Antibody Leads to Anti-Tumor Activity"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwlistdisc { list-style-type: disc }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Immunome Publishes Preclinical Research Demonstrating that Inhibition of IL-38 Using an Antibody Leads to Anti-Tumor Activity<\/b><\/p>\n<p>EXTON, Pa.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.immunome.com%2F&amp;esheet=53405750&amp;newsitemid=20230523006031&amp;lan=en-US&amp;anchor=Immunome%2C+Inc.+%28Nasdaq%3A+IMNM%29&amp;index=1&amp;md5=17ad1ed7728d8e1a2375cb985d9220df\">Immunome, Inc. (Nasdaq: IMNM)<\/a>, a biopharmaceutical company utilizing a proprietary human memory B cell platform to discover and develop antibody therapeutics to improve patient care, today announced the publication of data highlighting efficacy of its preclinical IL-38 blocking antibody, titled \u201c<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.tandfonline.com%2Fdoi%2Ffull%2F10.1080%2F19420862.2023.2212673&amp;esheet=53405750&amp;newsitemid=20230523006031&amp;lan=en-US&amp;anchor=IL-38+blockade+induces+anti-tumor+immunity+by+abrogating+tumor-mediated+suppression+of+early+immune+activation&amp;index=2&amp;md5=6fdfe18ca83dd5ab47e9f0c1f1956ac2\">IL-38 blockade induces anti-tumor immunity by abrogating tumor-mediated suppression of early immune activation<\/a>,\u201d in the peer-reviewed journal <i>mAbs<\/i>. The data in the article demonstrates that antibody-based targeting of IL-38 reactivates the immunostimulatory anti-tumor mechanisms within the tumor microenvironment in preclinical testing.<\/p>\n<p>\n\u201cAlthough immune checkpoint inhibitors have transformed how we treat cancer, these therapies are only effective in a small subset of patients. This highlights a significant need for continued innovation in this space,\u201d said Matthew Robinson, Ph.D., Chief Technology Officer of Immunome. \u201cOur Discovery Engine identified IL-38 as a potentially interesting immuno-oncology target. Based on our work highlighting the antitumor activity associated with targeting this novel cytokine and its marked expression across a range of cancers, including head and neck, lung, gastroesophageal, and others, we believe targeting IL-38 could benefit a number of patients.\u201d<\/p>\n<p><b>Key highlights from the study are:<\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li>\nIL-38 is expressed across all stages of disease in a range of tumors of high unmet medical<i \/>need<\/p>\n<\/li>\n<li>\nAn anti-IL-38 antibody, identified by Immunome, inhibits tumor growth in two <i>in-vivo<\/i> preclinical cancer models<\/p>\n<\/li>\n<li>\nTreatment in these models with the IL-38 blocking antibody resulted in increased levels of intra-tumoral chemokines<\/p>\n<\/li>\n<li>\nAnimals whose tumors fully resolved, when rechallenged, are resistant to tumor growth, suggesting the induction of immunological memory<\/p>\n<\/li>\n<\/ul>\n<p>\nPurnanand Sarma, Ph.D., President and Chief Executive Officer of Immunome, added, \u201cThese initial preclinical results support both the continued development and the approach we have taken in our patent filings for our anti-IL-38 program. We remain committed to leveraging the full power of our technology platform to continue advancing new and potentially transformative options for cancer patients.\u201d<\/p>\n<p><b>About Immunome<\/b><\/p>\n<p>\nImmunome is a biopharmaceutical company that utilizes its proprietary human memory B cell platform to discover and develop antibody therapeutics to improve patient care. The company\u2019s focus is on discovering and developing therapeutics in oncology internally and in collaboration with our partners. For more information, please visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.immunome.com&amp;esheet=53405750&amp;newsitemid=20230523006031&amp;lan=en-US&amp;anchor=www.immunome.com&amp;index=3&amp;md5=d3856e7fb15d7c1e3aca858cf5d7ce13\">www.immunome.com<\/a> or follow us on <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FImmunome&amp;esheet=53405750&amp;newsitemid=20230523006031&amp;lan=en-US&amp;anchor=Twitter&amp;index=4&amp;md5=c3ca2381b213ceb7a814377f3f5ccf31\">Twitter<\/a> and <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fimmunome-inc-&amp;esheet=53405750&amp;newsitemid=20230523006031&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=5&amp;md5=47876b03a32f2d5f8ffbe947b6eb41eb\">LinkedIn<\/a>.<\/p>\n<p><b>About Immunome\u2019s Discovery Engine<\/b><\/p>\n<p>\nImmunome\u2019s proprietary Discovery Engine identifies novel therapeutic antibodies and their targets through an unbiased interrogation of human memory B cells, highly educated components of the immune system, isolated from patients. Memory B cells are key elements in the human immune system response to disease as they produce specific, high-affinity antibodies that bind to cancer antigens or pathogens. Immunome\u2019s Discovery Engine incorporates high-throughput screening to enable efficient, unbiased, broad, and deep functional evaluation of patient memory B cell repertoires to identify antibodies directed at novel targets. The functional data we generate differentiates our approach from those that use deep sequencing of B cells to identify dominant clones that are common within and across patients and assumes genomic dominance is a hallmark of therapeutic utility.<\/p>\n<p><b>Forward-Looking Statements<\/b><\/p>\n<p>\nThis press release contains \u201cforward-looking statements\u201d intended to qualify for the \u201csafe harbor\u201d from liability established by the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements include, without limitation, express or implied statements that are not historical fact regarding matters such as: Immunome\u2019s ability to achieve anticipated discovery, development and commercial milestones; the timing and results of preclinical studies and clinical trials; regulatory submissions and actions; translation of preclinical data into clinical safety and efficacy; and therapeutic potential and benefits of, and possible need and demand for, Immunome\u2019s programs and development candidates. Forward-looking statements may be identified by the words \u201canticipate,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201cproject,\u201d \u201csuggest,\u201d \u201ccan,\u201d \u201cmay,\u201d \u201cwill,\u201d \u201ccould,\u201d \u201cshould,\u201d \u201cseek,\u201d \u201cpotential\u201d and similar words, although not all forward-looking statements contain such identifying words. These forward-looking statements are based on Immunome\u2019s current expectations and involve risks and uncertainties. Consequently, actual results may differ materially from those expressed or implied in the statements due to a number of factors, including, but not limited to Immunome\u2019s ability to execute on its R&amp;D strategy; Immunome\u2019s ability to fund operations and raise capital; Immunome\u2019s reliance on vendors; the competitive landscape; the fact that research and development data are subject to differing interpretations and assessments, including during the peer review\/publication process, in the scientific community generally, and by regulatory authorities; and the additional risks and uncertainties set forth more fully under the caption \u201cRisk Factors\u201d in Immunome\u2019s Annual Report on Form 10-K filed with the United States Securities and Exchange Commission (SEC) on March 16, 2023, and elsewhere in Immunome\u2019s other filings and reports with the SEC. Forward-looking statements contained in this announcement are made as of this date, and Immunome undertakes no duty to publicly update or revise any forward looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable law. In this press release, we may discuss our current and potential future product candidates that have not yet completed clinical trials or been approved for marketing by the U.S. Food and Drug Administration or other governmental authority, including expectations about their therapeutic potential and benefits thereof. No representation is made as to the safety or effectiveness of these current or potential future product candidates for the use for which such product candidates are being studied.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230523006031r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20230523006031\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20230523006031\/en\/<\/a><\/span><\/p>\n<p><b>Investor Contact<br \/>\n<\/b><br \/>Laurence Watts<br \/>\n<br \/>Managing Director<br \/>\n<br \/>Gilmartin, LLC<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:laurence@gilmartinir.com\">laurence@gilmartinir.com<\/a><\/p>\n<p><b>Media Contact<br \/>\n<\/b><br \/>Andrew Mielach<br \/>\n<br \/>Vice President, Account Management<br \/>\n<br \/>LifeSci Communications<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:amielach@lifescicomms.com\">amielach@lifescicomms.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> United States North America Pennsylvania<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Oncology Health Clinical Trials Research Science Pharmaceutical Biotechnology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\" \/>\n","protected":false},"excerpt":{"rendered":"<p>Immunome Publishes Preclinical Research Demonstrating that Inhibition of IL-38 Using an Antibody Leads to Anti-Tumor Activity EXTON, Pa.&#8211;(BUSINESS WIRE)&#8211;Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company utilizing a proprietary human memory B cell platform to discover and develop antibody therapeutics to improve patient care, today announced the publication of data highlighting efficacy of its preclinical IL-38 blocking antibody, titled \u201cIL-38 blockade induces anti-tumor immunity by abrogating tumor-mediated suppression of early immune activation,\u201d in the peer-reviewed journal mAbs. The data in the article demonstrates that antibody-based targeting of IL-38 reactivates the immunostimulatory anti-tumor mechanisms within the tumor microenvironment in preclinical testing. \u201cAlthough immune checkpoint inhibitors have transformed how we treat cancer, these therapies are only effective in a small subset of patients. &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/immunome-publishes-preclinical-research-demonstrating-that-inhibition-of-il-38-using-an-antibody-leads-to-anti-tumor-activity\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Immunome Publishes Preclinical Research Demonstrating that Inhibition of IL-38 Using an Antibody Leads to Anti-Tumor Activity&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-760107","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Immunome Publishes Preclinical Research Demonstrating that Inhibition of IL-38 Using an Antibody Leads to Anti-Tumor Activity - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/immunome-publishes-preclinical-research-demonstrating-that-inhibition-of-il-38-using-an-antibody-leads-to-anti-tumor-activity\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Immunome Publishes Preclinical Research Demonstrating that Inhibition of IL-38 Using an Antibody Leads to Anti-Tumor Activity - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Immunome Publishes Preclinical Research Demonstrating that Inhibition of IL-38 Using an Antibody Leads to Anti-Tumor Activity EXTON, Pa.&#8211;(BUSINESS WIRE)&#8211;Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company utilizing a proprietary human memory B cell platform to discover and develop antibody therapeutics to improve patient care, today announced the publication of data highlighting efficacy of its preclinical IL-38 blocking antibody, titled \u201cIL-38 blockade induces anti-tumor immunity by abrogating tumor-mediated suppression of early immune activation,\u201d in the peer-reviewed journal mAbs. The data in the article demonstrates that antibody-based targeting of IL-38 reactivates the immunostimulatory anti-tumor mechanisms within the tumor microenvironment in preclinical testing. \u201cAlthough immune checkpoint inhibitors have transformed how we treat cancer, these therapies are only effective in a small subset of patients. &hellip; Continue reading &quot;Immunome Publishes Preclinical Research Demonstrating that Inhibition of IL-38 Using an Antibody Leads to Anti-Tumor Activity&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/immunome-publishes-preclinical-research-demonstrating-that-inhibition-of-il-38-using-an-antibody-leads-to-anti-tumor-activity\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-05-23T20:10:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230523006031r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunome-publishes-preclinical-research-demonstrating-that-inhibition-of-il-38-using-an-antibody-leads-to-anti-tumor-activity\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunome-publishes-preclinical-research-demonstrating-that-inhibition-of-il-38-using-an-antibody-leads-to-anti-tumor-activity\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Immunome Publishes Preclinical Research Demonstrating that Inhibition of IL-38 Using an Antibody Leads to Anti-Tumor Activity\",\"datePublished\":\"2023-05-23T20:10:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunome-publishes-preclinical-research-demonstrating-that-inhibition-of-il-38-using-an-antibody-leads-to-anti-tumor-activity\\\/\"},\"wordCount\":986,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunome-publishes-preclinical-research-demonstrating-that-inhibition-of-il-38-using-an-antibody-leads-to-anti-tumor-activity\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230523006031r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunome-publishes-preclinical-research-demonstrating-that-inhibition-of-il-38-using-an-antibody-leads-to-anti-tumor-activity\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunome-publishes-preclinical-research-demonstrating-that-inhibition-of-il-38-using-an-antibody-leads-to-anti-tumor-activity\\\/\",\"name\":\"Immunome Publishes Preclinical Research Demonstrating that Inhibition of IL-38 Using an Antibody Leads to Anti-Tumor Activity - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunome-publishes-preclinical-research-demonstrating-that-inhibition-of-il-38-using-an-antibody-leads-to-anti-tumor-activity\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunome-publishes-preclinical-research-demonstrating-that-inhibition-of-il-38-using-an-antibody-leads-to-anti-tumor-activity\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230523006031r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2023-05-23T20:10:05+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunome-publishes-preclinical-research-demonstrating-that-inhibition-of-il-38-using-an-antibody-leads-to-anti-tumor-activity\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunome-publishes-preclinical-research-demonstrating-that-inhibition-of-il-38-using-an-antibody-leads-to-anti-tumor-activity\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunome-publishes-preclinical-research-demonstrating-that-inhibition-of-il-38-using-an-antibody-leads-to-anti-tumor-activity\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230523006031r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230523006031r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunome-publishes-preclinical-research-demonstrating-that-inhibition-of-il-38-using-an-antibody-leads-to-anti-tumor-activity\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Immunome Publishes Preclinical Research Demonstrating that Inhibition of IL-38 Using an Antibody Leads to Anti-Tumor Activity\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Immunome Publishes Preclinical Research Demonstrating that Inhibition of IL-38 Using an Antibody Leads to Anti-Tumor Activity - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/immunome-publishes-preclinical-research-demonstrating-that-inhibition-of-il-38-using-an-antibody-leads-to-anti-tumor-activity\/","og_locale":"en_US","og_type":"article","og_title":"Immunome Publishes Preclinical Research Demonstrating that Inhibition of IL-38 Using an Antibody Leads to Anti-Tumor Activity - Market Newsdesk","og_description":"Immunome Publishes Preclinical Research Demonstrating that Inhibition of IL-38 Using an Antibody Leads to Anti-Tumor Activity EXTON, Pa.&#8211;(BUSINESS WIRE)&#8211;Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company utilizing a proprietary human memory B cell platform to discover and develop antibody therapeutics to improve patient care, today announced the publication of data highlighting efficacy of its preclinical IL-38 blocking antibody, titled \u201cIL-38 blockade induces anti-tumor immunity by abrogating tumor-mediated suppression of early immune activation,\u201d in the peer-reviewed journal mAbs. The data in the article demonstrates that antibody-based targeting of IL-38 reactivates the immunostimulatory anti-tumor mechanisms within the tumor microenvironment in preclinical testing. \u201cAlthough immune checkpoint inhibitors have transformed how we treat cancer, these therapies are only effective in a small subset of patients. &hellip; Continue reading \"Immunome Publishes Preclinical Research Demonstrating that Inhibition of IL-38 Using an Antibody Leads to Anti-Tumor Activity\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/immunome-publishes-preclinical-research-demonstrating-that-inhibition-of-il-38-using-an-antibody-leads-to-anti-tumor-activity\/","og_site_name":"Market Newsdesk","article_published_time":"2023-05-23T20:10:05+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230523006031r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunome-publishes-preclinical-research-demonstrating-that-inhibition-of-il-38-using-an-antibody-leads-to-anti-tumor-activity\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunome-publishes-preclinical-research-demonstrating-that-inhibition-of-il-38-using-an-antibody-leads-to-anti-tumor-activity\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Immunome Publishes Preclinical Research Demonstrating that Inhibition of IL-38 Using an Antibody Leads to Anti-Tumor Activity","datePublished":"2023-05-23T20:10:05+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunome-publishes-preclinical-research-demonstrating-that-inhibition-of-il-38-using-an-antibody-leads-to-anti-tumor-activity\/"},"wordCount":986,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunome-publishes-preclinical-research-demonstrating-that-inhibition-of-il-38-using-an-antibody-leads-to-anti-tumor-activity\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230523006031r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunome-publishes-preclinical-research-demonstrating-that-inhibition-of-il-38-using-an-antibody-leads-to-anti-tumor-activity\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/immunome-publishes-preclinical-research-demonstrating-that-inhibition-of-il-38-using-an-antibody-leads-to-anti-tumor-activity\/","name":"Immunome Publishes Preclinical Research Demonstrating that Inhibition of IL-38 Using an Antibody Leads to Anti-Tumor Activity - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunome-publishes-preclinical-research-demonstrating-that-inhibition-of-il-38-using-an-antibody-leads-to-anti-tumor-activity\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunome-publishes-preclinical-research-demonstrating-that-inhibition-of-il-38-using-an-antibody-leads-to-anti-tumor-activity\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230523006031r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2023-05-23T20:10:05+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunome-publishes-preclinical-research-demonstrating-that-inhibition-of-il-38-using-an-antibody-leads-to-anti-tumor-activity\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/immunome-publishes-preclinical-research-demonstrating-that-inhibition-of-il-38-using-an-antibody-leads-to-anti-tumor-activity\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunome-publishes-preclinical-research-demonstrating-that-inhibition-of-il-38-using-an-antibody-leads-to-anti-tumor-activity\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230523006031r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230523006031r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunome-publishes-preclinical-research-demonstrating-that-inhibition-of-il-38-using-an-antibody-leads-to-anti-tumor-activity\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Immunome Publishes Preclinical Research Demonstrating that Inhibition of IL-38 Using an Antibody Leads to Anti-Tumor Activity"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/760107","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=760107"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/760107\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=760107"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=760107"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=760107"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}